Decode the GBA
Strengthen your Global Market Access Strategy
First-hand German reimbursement expertise, combined with an international health-system perspective, for pharmaceutical and biotech leaders making complex decisions in rare disease, orphan drugs, and advanced therapies.
Shape your clinical development strategy with future reimbursement in mind.
Drawing on my first-hand experience within the GBA and my background in international health and health policy, I help pharmaceutical and biotech leaders evaluate their options, anticipate reimbursement considerations, and make better-informed decisions from development through market access.
Through MBM Future Health, I provide independent strategic advice on GBA, AMNOG, German reimbursement, and broader market-access challenges.
I provide tailored strategic advice on the G-BA procedures and reimbursement decisions relevant to your medicine.
Your unique benefits
G-BA Expertise
You benefit from my long-standing experience at the GBA.
Your Personal Expert
Work directly with a senior expert throughout your engagement.
Lean Operations
You align your efforts with GBA expectations.
High Value
Your resources are allocated effectively.
Orphan Drug Specialist
Global Reach
Receive personalised advice wherever your organisation is based.
About
Meriem Bouslouk-Marx, MBM Future Health
Dr. Meriem Bouslouk-Marx
GBA and AMNOG strategy
Orphan-drug and rare-disease reimbursement strategy
Cell and Gene Therapy
Joint Scientific Consultation preparation
Medical background
International health-system and access assessments
Expert Speaker
Coming together is a beginning.
Keeping together is progress.
Working together is success.
Henry Ford
Get in touch via LinkedIn:
